A Study of BGM0504 in Early T2DM With Obesity
NCT07743983 on ClinicalTrials.gov · last registry update 2026-08-04
Recruiting now, toward 372 participants. Due to report 30 September 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from Baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 372
- Started
- 2026-08-30
- Primary completion
- 2028-09-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from Baseline
Conditions studied
Type 2 Diabetes (T2DM)
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.